Loading
A phase 1 trial of UBX-303-1 run by Ubix Therapeutics, Inc., now recruiting.
UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies is a phase 1 interventional study registered as NCT06590961 by Ubix Therapeutics, Inc., with 94 participants planned, started 2025-02-20. Conditions recorded: Relapsed/Refractory B-cell Malignancies. Interventions recorded: UBX-303061.
Shares Ubix Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ubix Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/